The terms of the agreement entail that Eli Lilly and Company (NYSE:LLY) will acquire Orna, and the latter’s shareholders could receive up to $2.4 billion in cash, inclusive of an upfront payment and ...

Apple stock is seeing a boost from the launch of the latest iteration of its flagship product, which has been well received ...

The firm expects its lead CAR T-cell therapy TPST-2003 to begin a Phase IIb registrational trial by the end of this year.

As its GLP-1 rival goes after compounders, Eli Lilly and Co. started the week with news beyond its diabetes and obesity franchise. The company, which disclosed a new agreement with Innovent Biologics ...

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical ...

It's the latest in a string of science-focused deals that the pharmaceutical giant has made over the past 12 months as its ...

Eli Lilly to buy Orna Therapeutics, which focuses on ‘in vivo’ CAR-T for autoimmune diseases, for $2.4 billion ...

The restaurant, located in the former Carrabba’s Italian Grill at 5110 Poplar Ave., officially opens with a ribbon-cutting ...

Experience unparalleled networking, mentorship and inspiration as powerful women across generation unite in Abu Dhabi.

Huawei’s and Xiaomi’s flagship devices are packed with impressive features, but Apple is dominating the Chinese smartphone ...

The UK-based AI-compute power service provider VivoPower is changing its digital asset exposure after agreeing to transfer ...